Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-06 Purchase | 2024-03-08 4:33 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 30,000 | $6.98 | $209,400 | 1,126,381 (Indirect Direct) | View |
| 2024-02-23 Sale | 2024-02-26 7:01 pm | GLAUKOS Corp | GKOS | Foley Mark J Director | 4,560 | $92.87 | $423,487 | 33,220 (Direct) | View |
| 2023-08-03 Sale | 2023-08-04 5:07 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 26,279 | $22.57 | $593,151 | 951,288 (Indirect Direct) | View |
| 2023-07-03 Sale | 2023-07-05 9:11 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 26,279 | $24.94 | $655,333 | 977,567 (Indirect Direct) | View |
| 2023-06-09 Sale | 2023-06-13 8:09 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 31,279 | $30.72 | $960,928 | 1,002,846 (Indirect Direct) | View |
| 2023-05-15 Sale | 2023-05-16 8:29 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 70,447 | $34.55 | $2,433,725 | 1,034,125 (Indirect Direct) | View |
| 2023-03-09 Sale | 2023-03-09 9:45 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 70,390 | $31.59 | $2,223,360 | 934,264 (Indirect Direct) | View |
| 2021-11-29 Purchase | 2021-11-29 9:24 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 40,000 | $12.9 | $515,924 | 879,978 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-06-30 Option Award | 2024-07-02 5:47 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 1,000 | $2.1845 | 1,106,848 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 8:56 pm | 2025-05-30 2034-05-30 | GLAUKOS Corp | GKOS | Foley Mark J Director | 2,962 | $0 | 36,182 (Direct) | View |
| 2024-03-15 Tax Withholding | 2024-03-19 6:43 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 20,533 | $5.305 | 1,105,848 (Direct) | View |
| 2024-02-29 Option Award | 2024-03-04 4:33 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 70,750 | $0 | 1,096,381 (Direct) | View |
| 2024-02-23 Exercise | 2024-02-26 7:01 pm | N/A 2024-07-10 | GLAUKOS Corp | GKOS | Foley Mark J Director | 10,000 | $0 | 33,220 (Direct) | View |
| 2024-02-23 Exercise | 2024-02-26 7:01 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 10,000 | $7.275 | 33,220 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 4:45 pm | 2025-02-15 2028-01-31 | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 1,070,001 | $0 | 1,070,001 (Direct) | View |
| 2023-12-31 Option Award | 2024-01-03 4:47 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 264 | $7.47 | 1,025,631 (Direct) | View |
| 2023-08-11 Tax Withholding | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 48,064 | $18.91 | 1,025,367 (Direct) | View |
| 2023-08-11 Option Award | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 122,143 | $0 | 1,025,367 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 9:11 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 1,000 | $15.61 | 977,567 (Direct) | View |
| 2023-06-01 Option Award | 2023-06-05 8:14 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 3,230 | $0 | 27,780 (Direct) | View |
| 2022-02-02 Option Award | 2023-05-16 8:29 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 175,649 | $0 | 1,034,125 (Direct) | View |
| 2023-03-15 Tax Withholding | 2023-03-17 3:22 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 5,341 | $30.65 | 928,923 (Direct) | View |
| 2022-09-22 Option Award | 2023-03-09 9:45 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 175,649 | $0 | 934,264 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-04 5:58 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 2,948 | $0 | 24,550 (Direct) | View |
| 2022-12-31 Option Award | 2023-01-03 4:28 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 605 | $12.18 | 829,005 (Direct) | View |
| 2022-10-13 Tax Withholding | 2022-10-14 7:02 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 49,274 | $26.97 | 828,400 (Direct) | View |
| 2022-06-30 Option Award | 2022-07-05 6:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 1,000 | $11.75 | 877,674 (Direct) | View |
| 2022-06-02 Option Award | 2022-06-06 7:55 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 4,364 | $0 | 21,602 (Direct) | View |
| 2022-03-15 Tax Withholding | 2022-03-17 5:54 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J Chief Executive Officer | 3,304 | $15.79 | 876,674 (Direct) | View |
| 2022-02-02 Option Award | 2022-02-04 8:35 pm | N/A 2032-02-01 | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 143,354 | $0 | 143,354 (Direct) | View |
| 2022-01-03 Option Award | 2022-01-05 8:55 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 2,486 | $0 | 17,238 (Direct) | View |
| 2021-10-13 Tax Withholding | 2021-10-15 8:00 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 42,096 | $23.08 | 839,978 (Direct) | View |
| 2021-06-30 Other | 2021-07-02 7:52 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 882 | $24.09 | 882,956 (Direct) | View |
| 2021-06-03 Option Award | 2021-06-07 7:04 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 2,382 | $0 | 14,752 (Direct) | View |
| 2021-02-02 Option Award | 2021-02-04 9:10 pm | N/A 2031-02-01 | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 114,380 | $0 | 954,857 (Direct) | View |
| 2021-01-04 Option Award | 2021-01-06 9:30 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 1,184 | $0 | 12,370 (Direct) | View |
| 2020-10-13 Tax Withholding | 2020-10-15 6:57 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 66,106 | $27.62 | 840,477 (Direct) | View |
| 2020-07-23 Option Award | 2020-10-15 6:57 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 315,352 | $0 | 840,477 (Direct) | View |
| 2020-09-30 Option Award | 2020-10-02 8:33 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 301,000 | $0 | 591,231 (Direct) | View |
| 2020-09-30 Tax Withholding | 2020-10-02 8:33 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 143,269 | $25.14 | 591,231 (Direct) | View |
| 2020-06-16 Option Award | 2020-06-18 7:10 pm | N/A N/A | SI-BONE Inc. | SIBN | Foley Mark J Director | 8,797 | $0 | 8,797 (Direct) | View |
| 2020-06-03 Option Award | 2020-06-05 9:51 pm | N/A N/A | GLAUKOS Corp | GKOS | Foley Mark J Director | 3,900 | $0 | 11,186 (Direct) | View |
| 2020-01-23 Option Award | 2020-01-24 8:22 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President | 200,000 | $0 | 413,500 (Direct) | View |